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1. INTRODUCTION {#jcmm15138-sec-0001}
===============

Prostate cancer (PCa) is one of the most commonly diagnosed male malignancies and the second leading cause of cancer‐related death in men.[1](#jcmm15138-bib-0001){ref-type="ref"}, [2](#jcmm15138-bib-0002){ref-type="ref"} Unfortunately, most androgen‐dependent PCa (ADPC) inevitably progresses to castration‐resistant prostate cancer (CRPC) after androgen ablation therapy.[3](#jcmm15138-bib-0003){ref-type="ref"}, [4](#jcmm15138-bib-0004){ref-type="ref"} Metastasis is a complicated and multi‐step process. Invasion and distant metastasis are significantly associated with the prognosis of PCa. The prognosis was poor in patients with metastatic PCa because no curative treatment is currently available.

Co‐ordinated reorganization of the actin cytoskeleton is essential to tumour invasion and metastasis.[5](#jcmm15138-bib-0005){ref-type="ref"}, [6](#jcmm15138-bib-0006){ref-type="ref"}, [7](#jcmm15138-bib-0007){ref-type="ref"} LIM kinase 1 (LIMK1) is one of the members of the LIM kinase protein family.[6](#jcmm15138-bib-0006){ref-type="ref"}, [8](#jcmm15138-bib-0008){ref-type="ref"} Previous studies[6](#jcmm15138-bib-0006){ref-type="ref"}, [8](#jcmm15138-bib-0008){ref-type="ref"}, [9](#jcmm15138-bib-0009){ref-type="ref"}, [10](#jcmm15138-bib-0010){ref-type="ref"}, [11](#jcmm15138-bib-0011){ref-type="ref"} demonstrated that LIMK played an essential role in regulating the polymerization of actin through phosphorylation and inactivation of cofilin, which acted as the only downstream effector of LIMK1. Cofilin can be inactivated by LIMK1 when its Ser3 site was phosphorylated.[12](#jcmm15138-bib-0012){ref-type="ref"} Inactivated cofilin lost the ability of binding to actin filaments which improved the stability of F‐actin, resulting in the change of actin cytoskeleton.[13](#jcmm15138-bib-0013){ref-type="ref"} Several studies have now confirmed that the expression of LIMK1 is consistently elevated in the many kinds of tumours including breast cancer,[6](#jcmm15138-bib-0006){ref-type="ref"}, [14](#jcmm15138-bib-0014){ref-type="ref"} ovarian cancer,[15](#jcmm15138-bib-0015){ref-type="ref"}, [16](#jcmm15138-bib-0016){ref-type="ref"} colon cancer[17](#jcmm15138-bib-0017){ref-type="ref"}, [18](#jcmm15138-bib-0018){ref-type="ref"} and gastric cancer.[19](#jcmm15138-bib-0019){ref-type="ref"}, [20](#jcmm15138-bib-0020){ref-type="ref"} However, researchers have paid little attention to the role of LIMK1 in prostate cancer. Several studies have reported that LIMK can promote the invasive and metastatic ability of tumours.[8](#jcmm15138-bib-0008){ref-type="ref"}, [17](#jcmm15138-bib-0017){ref-type="ref"} What is more, it also participated in many kinds of biological behaviours including angiogenesis, proliferation, cell cycle and migration.[14](#jcmm15138-bib-0014){ref-type="ref"}, [21](#jcmm15138-bib-0021){ref-type="ref"}, [22](#jcmm15138-bib-0022){ref-type="ref"}, [23](#jcmm15138-bib-0023){ref-type="ref"} Thus, LIMK1 has great potential to be a therapeutic target to prevent the invasion and metastasis of PCa.

This study hypothesized that LIMK1 was high expression in PCa and was involved in the invasion and metastasis of PCa. The expression of LIMK1 in PCa was determined by immunohistochemistry, and the relationship between the expression of LIMK1 and the invasion, metastasis, and prognosis of PCa was analysed.

2. MATERIALS AND METHODS {#jcmm15138-sec-0002}
========================

2.1. Ethics {#jcmm15138-sec-0003}
-----------

This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Fujian Medical University. Written informed consents were obtained from all patients.

2.2. Tissue specimen and data collection {#jcmm15138-sec-0004}
----------------------------------------

A total of 279 specimens of PCa tissue were collected from the patients who underwent radical prostatectomy from January 2012 to September 2015. All specimens were pathologically confirmed as primary prostate adenocarcinoma. Patients without any preoperative endocrine therapy, chemotherapy, radiotherapy, and immunotherapy were included. The age of patients ranged from 48 to 78 years, with an average of 68.45 ± 6.92 years. The stage of PCa was classified based on the Union for International Cancer Control (UICC)‐TNM classification. Fifty benign prostatic hyperplasia specimens were treated as control.

2.3. Follow‐up {#jcmm15138-sec-0005}
--------------

Patients with total prostate‐specific antigen (PSA) level less than 0.01 ng/mL were followed up for 1 month after radical prostatectomy. The follow‐up started from the date of the operation until the occurrence of the biochemical relapse. The follow‐up time ranged from 6 to 36 months. The exclusion criteria were as follows: patients who received adjuvant radiotherapy and/or endocrine therapy during follow‐up, with positive lymph node metastasis and with insufficient follow‐up data. Finally, a total of 163 patients were included in the analysis of biochemical recurrence. The follow‐up protocol[24](#jcmm15138-bib-0024){ref-type="ref"} was as follows: the first month after surgery; then every 3 months after surgery for 2 years; and afterwards every 6 months since the third year. The follow‐up was ended when biochemical recurrence occurred before September 2015. The total follow‐up time was 9 to 95 months, and the median follow‐up time was 55 months; the total biochemical recurrence rate was 17.18% (28/163), and the median biochemical recurrence time was 25 months (ranged from 10 to 67 months).

2.4. Construction of tissue microarray {#jcmm15138-sec-0006}
--------------------------------------

The paraffin‐embedded benign prostatic hyperplasia and PCa specimens were obtained from the department of pathology of the First Affiliated Hospital of Fujian Medical University. The paraffin‐embedded specimens were sliced and underwent H&E staining. The representative areas of the H&E staining sections were evaluated and confirmed by a senior pathologist in order to construct tissue microarray. A tissue microarray maker was designed to generate tissue microarrays by using 2 × 2 mm tissue cores in each case. Finally, tissue microarrays contain 5 × 10 tissue cores for both PCa and benign prostatic hyperplasia specimens in each were obtained and then be sliced continuously into 4‐μm‐thick sections.

2.5. Immunohistochemistry {#jcmm15138-sec-0007}
-------------------------

In the present study, staining of LIMK1 was performed by immunohistochemistry. Briefly, immunohistochemical staining for LIMK1 was performed on 4‐μm deparaffinized sections of formaldehyde‐fixed PCa and benign prostatic hyperplasia tissues using rabbit anti‐human LIMK1 polyclonal antibodies (Boster Biological Technology Co., Ltd.), and goat anti‐rabbit immunoglobulin G (Boster Biological Technology Co., Ltd.). Antibodies against LIMK1 were used in dilutions of 1:50. The sections for LIMK1 staining were treated with 0.01 mol/L citric acid buffer (PH 6.0l Fuzhou Maixin Biotech. Co., Ltd.) by a high‐pressure cooker 3 minutes for antigen retrieval.

The sections were then examined by light microscopy (Olympus) by two blinded pathologists. Any discrepancies were resolved by re‐reviewing the sections. Two semi‐quantitative methods and the total LIMK1 immunostaining score methods including staining intensity and the proportion of positive cells were described as follows.[25](#jcmm15138-bib-0025){ref-type="ref"}, [26](#jcmm15138-bib-0026){ref-type="ref"}, [27](#jcmm15138-bib-0027){ref-type="ref"}, [28](#jcmm15138-bib-0028){ref-type="ref"} The immunohistochemistry score of LIMK1 consists of two parts, including staining intensity and the proportion of positive cells. We classified the stating intensity as 0, absent; 1, weak; 2, moderate; and 3, strong. In terms of the proportion of positive cells, we defined the proportion as 0, \<5%; 1, 5%‐25%; 2, 26%‐50%; 3, 51%‐75%; and 4, \>75%. The immunohistochemistry score of LIMK1 was calculated utilizing the staining intensity score multiplied by the value of the percentage positivity score. The value of the LIMK1 immunohistochemistry score was ranged from 0 to 9. The expression level of LIMK1 was defined as '−' (scores 0‐1), '+' (scores 2‐3), '++' (scores 4‐5) and '+++' (scores ≥ 6).

2.6. Statistical methods {#jcmm15138-sec-0008}
------------------------

SPSS 21.0 statistical software (SPSS Inc) was used for all statistical analyses. The qualitative data were compared using the independent sample chi‐square test or Fisher exact test. The quantitative data were analysed using independent samples *t* test, Mann‐Whitney U test, Kruskal‐Wallis test or ANOVA. Kaplan‐Meier and the log‐rank test were used to compare the biochemical recurrence‐free survival in each group. *P* \< .05 was considered statistically significant.

3. RESULTS {#jcmm15138-sec-0009}
==========

3.1. The different expression of LIMK1 between benign prostatic hyperplasia and PCa tissues {#jcmm15138-sec-0010}
-------------------------------------------------------------------------------------------

A total of 215 cases of LIMK1‐positive expression were seen in 279 cases of PCa tissues, while a total 13 cases of LIMK1‐positive expression were observed in 50 cases of benign prostatic hyperplasia tissues. LIMK1 was mainly expressed in the cytoplasm of positive cells. The results demonstrated that the positive expression rate of LIMK1 in PCa tissues was significantly higher than that of benign prostatic hyperplasia tissues (77.1% vs 26.0%, respectively; *P* \< .001; Table [1](#jcmm15138-tbl-0001){ref-type="table"}; Figure [1](#jcmm15138-fig-0001){ref-type="fig"}).

###### 

The expression of LIMK1 in prostate cancer tissue and benign prostatic hyperplasia tissue

  Group   LIMK1 expression   Positive rate (%)   *P* value               
  ------- ------------------ ------------------- ----------- ---- ------ --------
  BPH     37                 10                  3           0    26.0   \<.001
  Pca     64                 68                  73          74   77.1    

John Wiley & Sons, Ltd

![Tissue microarray containing normal prostate, benign prostate hyperplasia and prostate cancer tissues was immunostained with a monoclonal anti‐LIMK1 antibody. A, Benign prostatic hyperplasia tissues, 40×; B, prostate cancer tissue, 40×](JCMM-24-4698-g001){#jcmm15138-fig-0001}

3.2. The different expression of LIMK1 between PCa tissues and corresponding lymph node metastases specimens {#jcmm15138-sec-0011}
------------------------------------------------------------------------------------------------------------

A total of 40 cases of positive lymph node metastases specimens and corresponding PCa tissues were collected for immunohistochemistry. The results demonstrated that the positive expression of LIMK1 in lymph node metastases specimens was higher than that of corresponding PCa tissues (*P* = .002; Table [2](#jcmm15138-tbl-0002){ref-type="table"}; Figure [2](#jcmm15138-fig-0002){ref-type="fig"}).

###### 

The expression of LIMK1 in prostate cancer and paired lymph node

  Group                 LIMK1 expression                  *P* value
  --------------------- ------------------ ---- ---- ---- -----------
  Positive lymph node   0                  5    8    27   .002
  Prostate cancer       3                  10   16   11    

John Wiley & Sons, Ltd

![The expression of LIMK1 in positive lymph node metastasis tissue was higher than that in prostate cancer tissue. (A and B, prostate cancer tissue; C and D, lymph node metastasis; A and C, ×100; B and D, ×400)](JCMM-24-4698-g002){#jcmm15138-fig-0002}

3.3. The relationship between LIMK1 expression and clinicopathological features of PCa patients {#jcmm15138-sec-0012}
-----------------------------------------------------------------------------------------------

The expression of LIMK1 was significantly associated with the prostate volume, PSA level, PSA density, Gleason score, T stage, lymph node metastases, extracapsular extension and seminal vesicle invasion, and positive surgical margin (*P* \< .05, Table [3](#jcmm15138-tbl-0003){ref-type="table"}). However, the expression of LIMK1 was not associated with the age of patients. Moreover, the strong staining of LIMK1 was seen in the low differentiation, high stage and lymph node metastasis specimens (Figure [3](#jcmm15138-fig-0003){ref-type="fig"}).

###### 

Association of LIMK1 expression with clinicopathological features of prostate cancer

  Variables                  N            LIMK1 expression   *P* value                           
  -------------------------- ------------ ------------------ ----------- ----------- ----------- -------------------------------------------------
  Total, n (%)               279          64                 68          73          74           
  Age (years)                                                                                    
  \<70                       136 (48.7)   31 (48.4)          36 (52.9)   33 (45.2)   36 (48.6)   .839
  ≧70                        143 (51.3)   33 (51.6)          32 (27.1)   40 (54.8)   38 (51.4)   
  Prostate volume (cm^3^)                                                                        
  ≤35                        99 (35.5)    33 (51.6)          43 (63.2)   15 (20.5)   8 (10.8)    \<.001[\*](#jcmm15138-note-0003){ref-type="fn"}
  \>35                       180 (64.5)   31 (48.4)          25 (36.8)   58 (79.5)   66 (89.2)   
  PSA (ng/mL)                                                                                    
  \<10                       42 (15.1)    12 (18.8)          18 (26.5)   6 (8.2)     6 (8.1)     .028[\*](#jcmm15138-note-0003){ref-type="fn"}
  10‐20                      182 (65.2)   39 (60.9)          38 (55.9)   50 (68.5)   55 (74.3)   
  \>20                       55 (19.7)    13 (20.3)          12 (17.6)   17 (23.3)   13 (17.6)   
  PSAD (ng/mL·cm^3^)                                                                             
  \<0.15                     18 (6.5)     2 (3.1)            11 (16.2)   2 (2.7)     3 (4.1)     .002[\*](#jcmm15138-note-0003){ref-type="fn"}
  ≥0.15                      261 (93.5)   62 (96.9)          57 (83.8)   71 (97.3)   71 (95.9)   
  Gleason score                                                                                  
  2‐6                        72 (25.8)    35 (54.7)          24 (35.3)   10 (13.7)   3 (4.1)     \<.001[\*](#jcmm15138-note-0003){ref-type="fn"}
  7                          141 (50.5)   19 (29.7)          33 (48.5)   39 (53.4)   50 (67.6)   
  8‐10                       66 (23.7)    10 (15.6)          11 (16.2)   24 (32.9)   21 (28.4)   
  cT stage                                                                                       
  T1                         42 (15.1)    28 (43.8)          6 (8.8)     4 (5.5)     4 (5.4)     \<.001[\*](#jcmm15138-note-0003){ref-type="fn"}
  T2                         192 (68.8)   31 (48.4)          60 (88.2)   56 (76.7)   45 (60.8)   
  T3                         45 (16.1)    5 (7.8)            2 (2.9)     13 (17.8)   25 (33.8)   
  Lymph node metastasis                                                                          
  Yes                        95 (34.1)    4 (6.3)            17 (25.0)   32 (43.8)   42 (56.8)   \<.001[\*](#jcmm15138-note-0003){ref-type="fn"}
  No                         184 (65.9)   60 (93.8)          51 (75.0)   41 (56.2)   32 (43.2)   
  Extracapsular extension                                                                        
  Yes                        45 (16.1)    5 (7.8)            2 (2.9)     13 (17.8)   25 (33.8)   \<.001[\*](#jcmm15138-note-0003){ref-type="fn"}
  No                         234 (83.9)   59 (92.2)          66 (97.1)   60 (82.2)   49 (66.2)   
  Seminal vesicle invasion                                                                       
  Yes                        14 (5.0)     0 (0.0)            1 (1.5)     7 (9.6)     6 (8.1)     .016[\*](#jcmm15138-note-0003){ref-type="fn"}
  No                         265 (95.0)   64 (100.0)         67 (98.5)   66 (90.4)   68 (91.9)   
  Positive surgical margin                                                                       
  Yes                        33 (11.8)    6 (9.4)            3 (4.4)     9 (12.3)    15 (20.3)   .028[\*](#jcmm15138-note-0003){ref-type="fn"}
  No                         246 (88.2)   58 (90.6)          65 (95.6)   64 (87.7)   59 (79.7)   

*P* \< .05.

John Wiley & Sons, Ltd

![The expression of LIMK1 in prostate cancer. LIMK1 is strong staining in poorly differentiated, high stage and positive lymph node metastasis tissue (×400)](JCMM-24-4698-g003){#jcmm15138-fig-0003}

Subsequently, subgroup analysis stratified by the lymph node metastasis was analysed. The results demonstrated that lymph node metastases were significantly associated with the preoperative PSA level, postoperative Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin and the LIMK1 expression (*P* \< .05, Table [4](#jcmm15138-tbl-0004){ref-type="table"}). However, lymph node metastases were not associated with the age, body mass index, prostate volume, the proportion of positive biopsy cores and PSA density (*P* \> .05, Table [4](#jcmm15138-tbl-0004){ref-type="table"}).

###### 

Association of clinicopathological features with lymph node metastasis of prostate cancer

  Variables                         N            Lymph node metastasis   *P* value   
  --------------------------------- ------------ ----------------------- ----------- -------------------------------------------------
  Total, n (%)                      279          184                     95           
  Age (years)                                                                        
  \<70                              136 (48.7)   91 (49.5)               45 (47.4)   .801
  ≧70                               143 (51.3)   93 (50.5)               50 (52.6)   
  BMI                                                                                
  ≤25                               142 (50.9)   99 (53.8)               43 (45.3)   .207
  \>25                              137 (49.1)   85 (46.2)               52 (54.7)   
  Prostate volume (cm^3^)                                                            
  ≤35                               99 (35.5)    66 (35.9)               33 (34.7)   .895
  \>35                              180 (64.5)   118 (64.1)              62 (65.3)   
  Percentage of positive biopsies                                                    
  \<50                              176 (63.1)   117 (63.6)              59 (62.1)   .896
  ≥50                               103 (36.9)   67 (36.4)               36 (37.9)   
  PSA (ng/mL)                                                                        
  \<10                              42 (15.1)    34 (18.5)               8 (8.4)     .015[\*](#jcmm15138-note-0004){ref-type="fn"}
  10‐20                             182 (65.2)   121 (65.8)              61 (64.2)   
  \>20                              55 (19.7)    29 (15.8)               26 (27.4)   
  PSAD (ng/mL·cm^3^)                                                                 
  \<0.15                            18 (6.5)     13 (7.1)                5 (5.3)     .619
  ≥0.15                             261 (93.5)   171 (92.9)              90 (94.7)   
  Gleason score                                                                      
  2‐6                               67 (36.4)    67 (36.4)               5 (5.3)     \<.001[\*](#jcmm15138-note-0004){ref-type="fn"}
  7                                 80 (43.5)    80 (43.5)               61 (64.2)   
  8‐10                              66 (20.1)    37 (20.1)               29 (30.5)   
  cT stage                                                                           
  T1                                42 (15.1)    37 (20.1)               5 (5.3)     .001[\*](#jcmm15138-note-0004){ref-type="fn"}
  T2                                192 (68.8)   124 (67.4)              68 (71.5)   
  T3                                45 (16.1)    23 (12.5)               22 (23.2)   
  Extracapsular extension                                                            
  Yes                               234 (83.9)   161 (87.5)              73 (76.8)   .026[\*](#jcmm15138-note-0004){ref-type="fn"}
  No                                45 (16.1)    23 (12.5)               22 (23.2)   
  Seminal vesicle invasion                                                           
  Yes                               265 (95.0)   179 (97.3)              86 (90.5)   .020[\*](#jcmm15138-note-0004){ref-type="fn"}
  No                                14 (5.0)     5 (2.7)                 9 (9.5)     
  Positive surgical margin                                                           
  Yes                               246 (88.2)   169 (91.8)              77 (81.1)   .011[\*](#jcmm15138-note-0004){ref-type="fn"}
  No                                33 (11.8)    15 (8.2)                18 (18.9)   
  LIMK1 expression                                                                   
  −                                 64 (22.9)    60 (32.6)               4 (4.2)     \<.001[\*](#jcmm15138-note-0004){ref-type="fn"}
  \+                                68 (24.4)    51 (27.7)               17 (17.9)   
  ++                                73 (26.2)    41 (22.3)               32 (33.7)   
  +++                               74 (26.5)    32 (17.4)               42 (44.2)   

*P* \< .05.

John Wiley & Sons, Ltd

The multivariate logistic regression analysis demonstrated that LIMK1 was independent risk factor for PCa lymph node metastasis (*P* \< .001, Table [5](#jcmm15138-tbl-0005){ref-type="table"}).

###### 

Logistic regression analysis of influencing factors for prostate cancer lymph node metastasis

  Variable                             OR (95% CI)           *P* value
  ------------------------------------ --------------------- -------------------------------------------------
  PSA (ng/mL, \<10 vs 10‐20 vs \>20)   1.653 (0.892‐3.065)   .111
  Gleason score (2‐6 vs 7 vs 8‐10)     1.626 (0.970‐2.725)   .065
  T stage (T1 vs T2 vs T3)             1.120 (0.338‐3.713)   .853
  Extracapsular extension              0.443 (0.098‐1.997)   .289
  Seminal vesicle invasion             1.469 (0.312‐6.921)   .626
  Positive surgical margin             1.379 (0.428‐4.440)   .590
  LIMK1 expression (−/+/++/+++)        2.289 (1.694‐3.092)   \<.001[\*](#jcmm15138-note-0005){ref-type="fn"}

*P* \< .05.

John Wiley & Sons, Ltd

3.4. The relationship between LIMK1 expression and biochemical recurrence {#jcmm15138-sec-0013}
-------------------------------------------------------------------------

Univariate Cox regression analysis demonstrated that higher proportion of positive biopsy cores, T stage, Gleason score, extracapsular extension, positive surgical margin and LIMK1 expression was associated with biochemical recurrence (*P* \< .05, Table [6](#jcmm15138-tbl-0006){ref-type="table"}). Multivariate Cox regression analysis revealed that up‐regulation of LIMK1 was independent risk factor for biochemical recurrence (*P* \< .05, Table [6](#jcmm15138-tbl-0006){ref-type="table"}).

###### 

Univariate and multivariate analysis of risk factors for biochemical recurrence

  Variable                                           Univariate             Multivariate                                                             
  -------------------------------------------------- ---------------------- ------------------------------------------------- ---------------------- -------------------------------------------------
  Age (years, \<70 vs ≥70)                           1.593 (0.735‐3.451)    .238                                                                      
  BMI (kg/m^2^, ≤25 vs \>25)                         1.745 (0.825‐3.694)    .145                                                                      
  Prostate volume (cm^3^, ≤35 vs \>35)               1.494 (0.658‐3.393)    .337                                                                      
  PSA (ng/mL, \<10 vs 10‐20 vs \>20)                 1.185 (0.633‐2.220)    .595                                                                      
  PSAD (ng/mL·cm^3^, \<0.15 vs ≥0.15)                1.856 (0.252‐13.675)   .544                                                                      
  Percentage of positive biopsies (%, \<50 vs ≥50)   0.347 (0.132‐0.914)    .032[\*](#jcmm15138-note-0006){ref-type="fn"}     0.523 (0.132‐2.079)    .357
  T stage (T1 vs T2 vs T3)                           2.798 (1.434‐5.460)    .003[\*](#jcmm15138-note-0006){ref-type="fn"}     0.295 (0.045‐1.947)    .205
  Gleason score (2‐6 vs 7 vs 8‐10)                   1.928 (1.170‐3.175)    .010[\*](#jcmm15138-note-0006){ref-type="fn"}     1.189 (0.514‐2.755)    .686
  Extracapsular extension (Yes vs No)                3.818 (1.679‐8.685)    .001[\*](#jcmm15138-note-0006){ref-type="fn"}     7.796 (0.908‐66.921)   .061
  Seminal vesicle invasion (Yes vs No)               1.293(0.176‐9.523)     .801                                                                      
  Positive surgical margin (Yes vs No）              4.188 (1.693‐10.358)   .002[\*](#jcmm15138-note-0006){ref-type="fn"}     1.068 (0.314‐3.640)    .916
  LIMK1 expression (−/+/++/+++)                      3.020 (2.004‐4.549)    \<.001[\*](#jcmm15138-note-0006){ref-type="fn"}   2.933 (1.118‐3.724)    \<.001[\*](#jcmm15138-note-0006){ref-type="fn"}

*P* \< .05.

John Wiley & Sons, Ltd

Kaplan‐Meier analysis indicated that up‐regulation LIMK1 was associated with shortened biochemical‐free survival (BFS) after radical prostatectomy (*P* \< .001, Figure [4](#jcmm15138-fig-0004){ref-type="fig"}).

![Non‐biochemical recurrence survival in patients with prostate cancer stratified by the different expression level of LIMK1 protein](JCMM-24-4698-g004){#jcmm15138-fig-0004}

4. DISCUSSION {#jcmm15138-sec-0014}
=============

The LIMK family consists of LIMK1 and LIMK2, which belongs to the serine protein kinase, and associated with actin polymerization and microtubule depolymerization.[29](#jcmm15138-bib-0029){ref-type="ref"} The expression of LIMK1 was mainly seen in the cytoplasm and can freely shuttle between normal nucleus and cytoplasm.[9](#jcmm15138-bib-0009){ref-type="ref"} The expression of LIMK was elevated in many kinds of tumours, especially highly invasive malignancies. LIMK 1 plays an important role in the invasion and metastases of tumours by regulating the actin cytoskeleton molecules.[14](#jcmm15138-bib-0014){ref-type="ref"}, [15](#jcmm15138-bib-0015){ref-type="ref"}, [17](#jcmm15138-bib-0017){ref-type="ref"} Recently, the significance of LIMK1 in tumorigenesis has aroused extensive concern.[6](#jcmm15138-bib-0006){ref-type="ref"}, [19](#jcmm15138-bib-0019){ref-type="ref"} There are many mechanisms regulating the activation of LIMKI. The activated LIMK1 is responsible for the stability of the cytoskeleton and the bond of external stimulation of the cells.[9](#jcmm15138-bib-0009){ref-type="ref"} The LIMK1 was in the cytoplasm and rapidly migrates back and forth between the nucleus and the cytoplasm.[11](#jcmm15138-bib-0011){ref-type="ref"}, [29](#jcmm15138-bib-0029){ref-type="ref"} When the cytoskeleton is assembled, LIMK1 deactivates the cofilin by phosphorylation of 3 serine residues, which reverses the process of actin depolymerization.[8](#jcmm15138-bib-0008){ref-type="ref"} It is reported that LIMK1 played an important role in regulating the transportation process of lysosome and endosome.[6](#jcmm15138-bib-0006){ref-type="ref"} In addition, Manetti et al[30](#jcmm15138-bib-0030){ref-type="ref"} also demonstrated that metastasis‐related gene is located on chromosome 7q11.2 and LIMK1 is also located on chromosome 7q11.2. These results indicated that LIMK1 may play an important role in tumour metastasis.

Lymph node metastasis frequently occurs in PCa, especially pelvic lymph node metastasis, which plays an important role in poor prognosis of PCa and is the key step of systemic metastasis.[31](#jcmm15138-bib-0031){ref-type="ref"} Nowadays, it is still controversial that pelvic lymph node dissection should be performed with radical prostatectomy. Some researchers[32](#jcmm15138-bib-0032){ref-type="ref"}, [33](#jcmm15138-bib-0033){ref-type="ref"} suggest that pelvic lymph node dissection can increase the accuracy of tumour stage and improve the prognosis of patients in some extent. However, for patients with pathological confirmed pTxN0 PCa, the lymph node dissection does not improve the prognosis, even in patients with high PSA level, high pathological stage, and extracapsular extension prior to the surgery.[34](#jcmm15138-bib-0034){ref-type="ref"}, [35](#jcmm15138-bib-0035){ref-type="ref"} So far, researchers suggested that patients with low‐risk PCa should avoid pelvic lymph node dissection, while patients with moderate‐risk or high‐risk PCa, especially high‐risk PCa, are recommended to underwent standard or extended pelvic lymph node dissection.[36](#jcmm15138-bib-0036){ref-type="ref"}, [37](#jcmm15138-bib-0037){ref-type="ref"} In general, however, there is still a lack of an effective way to predict the risk of lymph node metastasis preoperatively and evaluate the benefit obtained from the lymph node dissection. In this study, the expression of LIMK1 in positive lymph nodes and the corresponding primary PCa tissues was evaluated. The results demonstrated that the expression of LIMK1 in positive lymph nodes was higher than that of the corresponding primary lesions. Subgroup analysis stratified by the lymph node metastasis demonstrated that lymph node metastases were significantly associated with the preoperative PSA level, postoperative Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin and the LIMK1 expression. Moreover, the multivariate logistic regression analysis demonstrated that LIMK1 was independent risk factor for PCa lymph node metastasis. It is indicated that the expression of the LIMK1 could be treated as a predictor of the invasion and metastasis of PCa.

At present, there are many clinicopathological parameters to evaluate the risk of progression, metastasis and prognosis of PCa. The risk factors for biochemical recurrence included body mass index, preoperative PSA, the proportion of positive biopsy cores, pathological stage, extracapsular extension, seminal vesical invasion, lymph node metastasis, and positive surgical margin.[38](#jcmm15138-bib-0038){ref-type="ref"}, [39](#jcmm15138-bib-0039){ref-type="ref"}, [40](#jcmm15138-bib-0040){ref-type="ref"} However, the accuracy of these traditional clinicopathological factors for predicting the biochemical recurrence of PCa remains low.[41](#jcmm15138-bib-0041){ref-type="ref"} There is still no ideal and reliable marker for predicting the tumour growth, invasion and metastasis.[42](#jcmm15138-bib-0042){ref-type="ref"} Sen et al[43](#jcmm15138-bib-0043){ref-type="ref"} reported that the serum LIMK1 level in patients with hepatocellular carcinoma was significantly higher than those in patients with liver cirrhosis and normal individuals. The diagnostic accuracy of LIMK1 in the diagnosis of hepatocellular carcinoma was higher than that of AFP. In the study of cytotoxic chemotherapy of triple‐negative breast cancer, the expression of LIMK1 was associated with the prognosis of the cytotoxic chemotherapy.[44](#jcmm15138-bib-0044){ref-type="ref"} Manevich et al[45](#jcmm15138-bib-0045){ref-type="ref"} indicated that the expression of LIMK1 in PCa tissues was increased when compared with the adjacent PCa tissues. The elevated LIMK1 expression was also correlated with the occurrence of castration‐resistant PCa after surgery. The expression of LIMK1 increased in a short time was correlated with an increased risk of bone metastasis of PCa. Multivariate Cox regression analysis revealed that up‐regulation of LIMK1 was independent risk factor for biochemical recurrence. Kaplan‐Meier analysis indicated that up‐regulation LIMK1 was associated with shortened biochemical‐free survival (BFS) after radical prostatectomy. These results indicated that LIMK1 is an ideal and reliable biomarker to predict the risk of biochemical recurrence. For patients with an elevated expression of LIMK1, early use of adjuvant radiotherapy or endocrine therapy may postpone the occurrence of biochemical recurrence.

There are some limitations in this study. Firstly, this study was retrospectively designed. Secondly, the prognostic power of the number of positive lymph nodes with that of lymph node ratio was not analysed in this study.

In conclusion, LIMK1 was significantly up‐regulated in PCa and positive lymph node specimens and correlated with lymph node metastasis and shortened BFS of PCa. The underlying molecular mechanism of LIMK1 in PCa should be further evaluated.
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